• Canadian-based clean energy solutions innovator FuelPositive Corp. is focused on developing green ammonia as a more efficient and sustainable source of fuel than the popular fossil fuel alternative hydrogen
• FuelPositive’s Hydrogen-Ammonia Synthesizer technology provides the means of storing hydrogen as green ammonia for effective transportation and storage, with the option of easy conversion back to hydrogen for use in hydrogen fuel cells and other pure hydrogen applications
• The company is among a handful of entities that have noted Canada’s outsized support for fossil fuels recently, and plans to roll out its IP next year in “real world” demonstration pilot projects
• Carbon footprint reduction has gained global attention in recent years amid concerns about climate change resulting from pollutants, and policy representatives from around the world recently gathered in Scotland for the COP26 2021 United Nations Climate Change Conference to address related issues

When green energy innovator FuelPositive (TSX.V: NHHH) (OTCQB: NHHHF) commissioned an analysis of Canada’s green off-peak electricity capacity earlier this year to help measure the fuel needs and carbon emissions of the country’s transportation sector, FuelPositive was adding its own insights to a recent series of examinations of Canada’s renewable energy performance. Oil Change International, which tracks public finance of fossil fuels, reported last month that Canadian fossil fuel producers receive more public financial support than any others in the developed world, and that Canadian renewable energy received far less in public financial support than many other countries provide to their industries (https://ibn.fm/434r3). The report noted that both the federal government and Export Development Canada — the agency that handles most of the financing — have pledged they’ll reduce fossil fuel financing during the coming years, with the Liberal party setting a deadline of 2023. Export Development Canada expects to reduce support to the six most carbon-intensive sectors by 40% below 2018 levels before the deadline, according to the report. FuelPositive is in the business of developing and commercializing green energy solutions and gaining standout technology innovation in the sector through partnerships and acquisition, specifically in regard to “green ammonia” produced in a carbon-free manner for use in a variety of applications that contribute to environmental sustainability at a time when climate change is a profound concern for world governments. FuelPositive’s patent-pending green ammonia (“NH3”) technology is an advanced Hydrogen-Ammonia Synthesizer, a highly portable and scalable and modular system the company plans to introduce next year in “real world” demonstration pilot projects as it advances toward commercial production (https://ibn.fm/QPvbF). Carbon-free green ammonia has the potential to become a fossil fuel alternative — the company notes that planes, trains, ships, trucks, and other vehicles can be converted to run on ammonia as easily as they can be converted to run on propane instead of gasoline or diesel. Additionally, FuelPositive’s Hydrogen-Ammonia Synthesizer technology can convert air, water, and sustainable electricity to store hydrogen in the form of green ammonia, allowing hydrogen to be more efficiently stored or transported than it would be in liquid hydrogen form which requires high-pressure tanks and cryogenic storage temperatures. An end user can then easily convert the green ammonia back into hydrogen for use in producing electricity in a hydrogen fuel cell when that is required by transportation vehicles, according to the company. FuelPositive is also pursuing the development of green ammonia fuel cells which are a new and attractive alternative to hydrogen fuel cells. Following the latest international climate summit, branded COP26, many researchers have described hydrogen as the best source for generating renewable energy (https://ibn.fm/SRSx5) because when hydrogen burns, the only by-product is water. But hydrogen has traditionally been generated from fossil fuels, which only compounds the challenges of developing clean energy goals. Former California Gov. Arnold Schwarzenegger was expected to attend the COP26 2021 United Nations Climate Change Conference talks, which concluded Nov. 12, and appeared in the news prior to the summit as part of a wide-ranging interview in which he criticized some of the excuses policy advisers use for resisting transition to sustainable fuel sources. “They are liars, they are stupid. Or they don’t know how to do it, because we figured how to do it (in California),” Schwarzenegger told the BBC (https://ibn.fm/iFNDp). Schwarzenegger has built his own brand on performance fitness celebrity over the past several decades and, more recently, on environmental sustainability goals. He told the interviewer he was particularly alarmed at pollutants that result from shipping and suggested shopping locally is the most important thing individuals can do to cut carbon emissions. “Buy local products. Every time you buy something from overseas, that is evil for the environment — this is like the worst thing you can do. … You can have (international) competition but you have to be smart about it … because if people are dead, they are dead. It’s over.” For more information, visit the company’s website at www.FuelPositive.com. NOTE TO INVESTORS: The latest news and updates relating to NHHHF are available in the company’s newsroom at https://ibn.fm/NHHHF

• Multiple ongoing studies are researching the relationship between medical cannabis and cancer treatment
• The viability of clinical studies within the sector is hampered by lack of exact measurement of a patient’s intake
• RYAH Group intends to resolve this issue with the launch of it’s proprietary RYAH Smart Dry Herb Inhaler
• The company successfully delivered on its first Inhaler order in May 2021, and announced that they had received a follow-on order in November 2021

In 1980, The United States National Cancer Institute (“NCI”) began experimental distribution of a novel drug called Marinol, an oral form of THC (the primary active ingredient in cannabis), to cancer patients in San Francisco (https://ibn.fm/HE5vn). Just over a decade later, the city of San Francisco celebrated the passing of Proposition P in 1991, a revolutionary bill that legalized the use of medical cannabis within the city limits. There’s an abundance of evidence supporting the use of medical cannabis to treat cancer symptoms. Now, rather than just treating symptoms, science has begun to ask, “could cannabis be used to treat cancer itself”? A recognized leader in volume management technology for plant-based medicine, RYAH Group (CSE: RYAH) is in the middle of the action. RYAH develops innovative IoT products that capture powerful data insights and is on a mission to to transform patient care using big data and AI to reshape understanding and uses of plant-based medicines. The company’s robust artificial intelligence platform aggregates and correlates HIPAA-compliant patient data, which then helps doctors and patients personalize plant-based treatments to better predict treatment outcomes. Little wonder that RYAH devices and data are being used by a rapidly growing number of participants in plant-based clinical trials around the world. While clinical research into the relationship between medical cannabis consumption and cancer treatment is in the very early stages, initial studies have shown that THC and other cannabinoids bind to the endocannabinoid receptors on cancer cells, thereby interrupting the cell’s ability to signal. With limited intracellular signals, the studies have witnessed increased cancer cell apoptosis, reduced proliferation, migration, and metastasis (https://ibn.fm/rSirx). Two key constraints that have limited the viability of cannabis studies within an oncological setting are the highly variable nature of the cannabis plant and traditional methods of cannabis consumption that make patient intake challenging to measure. The RYAH Group intends to resolve this issue with the launch of their proprietary RYAH Smart Dry Herb Inhaler. The product is the first dry-herb inhaler that tracks and controls how much is inhaled, providing consistent and predictable results. The inhaler connects with the RYAH Health App, which features stat-tracking and presets for temperatures and measurements, all of which can be customized to individual needs and doctor recommendations. Moreover, the device also permits a post-session review mechanism that collects session data, an essential requirement for any clinical study. In June 2021, the RYAH Group announced that it had completed its first shipment of RYAH Smart Dry Herb Inhalers, which included delivery of approximately 10,000 RYAH Cartridges and QR codes, to an international clinic undertaking one of the world’s largest and most comprehensive clinical trials in plant-based medicine (https://ibn.fm/XkFrG). In early November, the company announced that it had received a separate, follow-on order for its proprietary Inhaler product from the same company (https://ibn.fm/gALMy). While it is far too early for patients to forego traditional oncological treatments in favor of standalone medical cannabis therapy, clinical trials worldwide seek to discern the relationship between medical cannabis consumption and cancer treatment. While the trials currently lie at a relatively nascent stage, RYAH Group and its diverse and proprietary volume control and management device portfolio are playing their part in what may, one day, turn out to be a genuinely revolutionary medical breakthrough. For more information, visit the company’s website at www.RYAHGroup.com. NOTE TO INVESTORS: The latest news and updates relating to RYAH are available in the company’s newsroom at https://ibn.fm/RYAH

• 1 in 8 adults are forecast to suffer from diabetes by 2024, with over 1 in 10 deaths in 2021 a direct result of the disease
• As many as 40% of Covid-19 related fatalities in the US also suffered from diabetes at the time of their passing
• Nemaura Medical is a medical technology company focused on developing non-invasive wearable diagnostic devices
• In addition to sugarBEAT, its flagship device, the company also recently announced the launch of MiBoKo, a combined application and non-invasive glucose sensor designed to help users track their metabolic scores

By 2024, the International Diabetes Federation (“IDF”) predicts that the number of people with diabetes is expected to rise to 1 in 8 adults. Nearly 7 million adults have died worldwide in 2021 so far due to diabetes or its related complications – astoundingly, accounting for over 1 in 10 global deaths from any cause. While enormous, that figure does not consider the lives lost to the novel coronavirus, which has shown to be particularly deadly for people with diabetes. A study found that having Type 1 or Type 2 diabetes tripled the risk of severe illness or death from COVID-19 (https://ibn.fm/laj37). “As many as 40% of the people that have died in the US from COVID-19 had diabetes,” said Dr. Robert Gabbay, chief scientific and medical officer for the American Diabetes Association. Founded in 2011, Nemaura Medical (NASDAQ: NMRD),  a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, set out to develop a single platform technology to measure blood markers at the surface of the skin. Since then, the company has evolved by creating wearable technologies and digital health care solutions that encourage and empower people to take charge of their health and well-being. The company’s flagship product, sugarBEAT(R), is a wearable, non-invasive and flexible Continuous Glucose Monitor (“CGM”) designed to help people with diabetes and prediabetes manage their glucose levels. The company has recently followed up with the release of the MiBoKo application. This service, which has been in development for the past 18 months, seeks to address a significant mass-market opportunity which the company believes could benefit roughly a third to half of the global population. The MiBoKo application uses a non-invasive glucose sensor to measure and monitor the user’s metabolic health scores, which are based on glucose tolerance or insulin resistance. Prediabetic patients, those facing obesity concerns, or individuals looking to monitor their glucose intake would all benefit from this application. A recent study carried out using anonymized health care data from a sample of over 16,000 people with both type 2 diabetes and COVID-19 found that people with type 2 diabetes who contracted Covid-19 were nearly 50% more likely to wind up in intensive care if they had mismanaged their blood sugar levels over the long-term, relative to those with better long-term glycaemic control (https://ibn.fm/8ySDC). With the COVID-19 virus rapidly gaining endemic status worldwide, diabetic and prediabetic patients are more at risk than ever before. By launching their unique and functional glucose monitoring devices, Nemaura Medical has sought to address this growing health risk, providing individuals afflicted with diabetes the world over with a more accessible, non-invasive method to monitor their health. For more information, visit the company websites at www.NemauraMedical.com. NOTE TO INVESTORS: The latest news and updates relating to NMRD are available in the company’s newsroom at https://ibn.fm/NMRD

• PlantX reported strong results for the three months ended September 30, 2021 (Q2 2022), with year-on-year increases in both gross revenue and gross profits
• Q2 2022 has seen PlantX roll out numerous initiatives designed to enhance its e-commerce impact, including launching as a third-party seller on Amazon Marketplace and Walmart Marketplace; opening new brick-and-mortar locations in California under its XMarket brand; and launching a meal delivery service
• The company also facilitated educational programming on plant-based lifestyles
• The accomplishments from these initiatives demonstrate PlantX’s increased effectiveness and commitment to its e-commerce expansion in line with its goal to add value to the plant-based industry

PlantX Life (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF), a company redefining the plant-based community through e-commerce initiatives, educational programs, and more, recently released its interim unaudited financials for the three and six months ended September 30, 2021, constituting Q2 and H1 2022 results (https://ibn.fm/B1wdW). Key Q2 2022 highlights from the November 29 announcement included a gross revenue of CA$2.8 million, representing a year-on-year increase of roughly CA$2.5 million from Q2 2021 figures. PlantX also recorded gross profits of $1.3 million in Q2 2022, an 8025% year-on-year growth compared to $15,913 recorded in Q2 2021. As of September 30, the company had working capital of $10.2 million, inclusive of cash of $9.6 million. In addition to the stellar year-on-year growth reported, Q2 2022 also saw the company make significant progress in diversification and implementation of new technology, the launch of physical retail stores, and facilitation of education programming on the plant-based lifestyle. PlantX launched as a third-party seller on Amazon Marketplace in both Canada and the United States as well as on Walmart Marketplace in the United States, further augmenting its e-commerce operations by leveraging Amazon’s and Walmart’s world-class e-commerce resources. The move is likely to help PlantX position itself as a leader in the plant-based space and increase its impact as it expands its in-house brands. The company also launched a meal delivery service, XFood, in Southern California with plans to later expand throughout the U.S. A collaborative effort between itself and celebrity chef Matthew Kenney, who is also PlantX’s partner at XMarket, XFood aims to reach as many people with plant-based options as possible. In addition, PlantX announced the launch of its redesigned Shopify-powered Canadian website. The refreshed site offers a modern design, upgraded functionality and search tools, and more straightforward navigation. Q2 2022 also saw PlantX implement novel initiatives that complement its e-commerce operations. For instance, the company launched new brick-and-mortar locations in San Diego, California, and Venice Beach, California, expanding the number of XMarket sites to three, with the third located in Squamish, British Columbia. At the same time, PlantX announced new physical locations opening up inside the Hudson Bay stores in Toronto and Ottawa (https://ibn.fm/EHDEh). Notably, PlantX’s XMarket brand represents the company’s redefined physical retail presence. The XMarket ecosystem, PlantX says, is focused on boosting brand awareness and customer engagement, improving plant-based education, creating new supply chain infrastructure, establishing a core consumer base, and driving sustainable e-commerce growth. “It has been an active quarter for PlantX as we continue to devote our efforts towards achieving our strategic expansion plan,” stated PlantX Founder Sean Dollinger. “From scaling our operational capabilities, to expanding our customer base and enhancing our educational pursuits, we have demonstrated increased effectiveness in line with our goal to add value and increase our impact in the fast-growing plant-based industry.” “As we approach the end of 2021, our focus is to support our community as best we can throughout the holiday season and advance our progress with creativity and passion,” Dollinger concluded. For more information, visit the company’s websites at www.PlantX.com, www.PlantX.ca, and https://investor.plantx.com/ and view PlantX for Plant-Based Investors. NOTE TO INVESTORS: The latest news and updates relating to PLTXF are available in the company’s newsroom at https://ibn.fm/PLTXF

Fashion can be fun but make no mistake, it can be profitable too. The global apparel market is coming off a historic decline caused by lockdowns, social distancing, and economic slowdowns due to the COVID-19 outbreak and the measures to contain it. COVID still lingers but the apparel market looks ripe for rebound and ready to hit new highs. During the lockdown, consumers strayed away from purchasing new apparel. However, apparel companies still have the potential to deliver good earnings and significant capital gains. Not only is the industry huge, but it also ripe for rebound with much higher seasonal demand during the holidays. Time to shed the sweatpants, get dressed for success and get serious about some apparel. Some the largest, most popular apparel labels are owned and operated by unfamiliar names like PVH Corp. (NYSE: PVH) which has multiple brands under its umbrella including Van Heusen, Tommy Hilfiger, and Calvin Klein among others. Formerly known as the Phillips-Van Heusen Corporation, PVH also licenses brands such as Kenneth Cole New York and Michael Kors. PVH is one of the largest global apparel companies in the world reporting $7.1 billion in 2020 revenues. PVH reported third-quarter fiscal 2021 results, where the bottom line surpassed the Zacks Consensus Estimate, while the top line missed the same. However, both metrics improved year over year. The Calvin Klein segment improved 22% year over year and the Tommy Hilfiger segment rose 12%. A top hedge fund, Pzena Investment Management, had $439 million invested in the stock at the end of September and in a strong indicator, an insider purchased 1,981 shares at $81 in September 2020. The company also noted in the Q3 report that holiday season sales are off to a solid start and management raised the fiscal 2021 view. Another name not quickly recognized as an apparel behemoth is VF Corporation (NYSE: VFC). Their brands include Dickies, JanSport, Kipling, The North Face, Timberland, Vans, and Supreme. The company controls 55% of the US backpack market across all of its brands, making it a major player in the clothing industry. Across all their segments, the VF Corporation generated close to $10.5 billion U.S. dollars in global revenue in 2020 and the company ranked first based on revenue of leading apparel companies worldwide in 2019. The company reported improved results for Q2 fiscal 2022 last October. Overall revenue from continuing operations increased 23 percent. Outdoor segment revenue increased 31 percent, Work segment revenue increased 18 percent, International revenue increased 18 percent, and Direct-to-Consumer revenue increased 32 percent. Full year fiscal 2022 revenue is now expected to be approximately $12.0 billion, reflecting growth of around 30 percent. An intriguing apparel name, Digital Brands Group, Inc. (NASDAQ: DBGI) (www.digitalbrandsgroup.co) is redefining retail and the customer experience with its digital first, curated group of lifestyle brands. The company currently offers contemporary womenswear through Bailey 44 (www.bailey44.com), premium denim and luxury essentials through DSTLD (www.dstld.com), and luxury menswear through ACE Studios (www.acesuits.com). Digital Brands Group’s unique business model is capitalizing on increased global digitization and the long-time fragmentation of the apparel and fashion markets. The company operates its brands on a decentralized basis with separate executive teams running each brand while consolidating marketing and technology contracts and cross marketing to each brand’s customers. Since going public last May, the company has rapidly gained traction and increased leverage by rolling up brands and creating scale. Digital Brands reported impressive Q3 2021 results last November -third quarter 2021 net revenue increased 75% year over year and the gross profit margin increased 96% year over year to 55.9%. DBGI also provided eye-popping net revenue guidance for fiscal year 2022 – an increase of 350% from 2021 with 2022 revenue expectations of $37.5M to $42.5M. The company forecasts positive EBITDA for 2022 as it leverages its shared services platform.  Commenting on the surging growth, Hil Davis, CEO of Digital Brands Group, stated “This forecasted increase of 350% in our year over revenue growth does not reflect any potential additional acquisitions, nor does it reflect any meaningful benefit from our expected increase in marketing spend.” Digital Brands expects continued growth through acquisitions and to continue to acquire companies this year and next. Though much smaller than other apparel brands, DBGI just might have the most upside potential. The stock is trading at the low end of it’s range and with so much growth potential if the company hits or exceeds guidance the high end of it’s range could be in the rear-view mirror. The holidays and the seasonal surge in apparel are fast approaching. This seems like the perfect time to celebrate, have fun, and position portfolios with apparel stocks.

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW) 8033 Sunset Blvd Suite 1037-IW Los Angeles, CA 90046 310.299.1717 Office www.InvestorWire.com Editor@InvestorWire.com

InvestorWire is part of the InvestorBrandNetwork.

Date: December 8-9, 2021 Venue: Hybrid, San Diego, CA The forthcoming Social Media Strategies Summit – Public Agencies & Government event will be held in an entirely digital format on December 8-9, 2021, by the Global Strategic Management Institute (“GSMI”), a cutting-edge conference production business focused on encouraging disruptive innovation. The virtual event is designed to help government agencies use social media to humanize their offices and engage with their communities. Attendees will have access to a carefully curated series of sessions and experienced speakers who will seek to address topics that can have the greatest impact on a social media strategy in the public sector. Senior-level marketing professionals choose SMSsummit year after year to stay up to date on the newest in social media marketing. This December 8-9, 2021, at SMSS Public Agencies and Government, use social media to humanize your agency and engage your communities! Some highlights of the event include:

• Learn new social media methods and share your experiences.
• Make connections with other government employees.
• Get answers to all of your social media questions.
• Learn how to deal with problems using techniques and recommendations.

Why Should You Attend It? SMSsummit is a great place to go for new social media ideas and community-building tactics. It brings together government and public-sector colleagues from around the world to share experiences and learn new social media methods.  Make connections with government employees from all over the country. The Social Media Strategy Summit offers an opportunity to get all of your social media questions answered through speaker Q&A, live chat, and discussions with other attendees. Make social media a point of pride for your team! This event will assist you in laying the groundwork for a long-term, scalable social media policy that allows your team to provide the best possible service to your constituents. Learn techniques and tips for dealing with the most pressing issues facing government agencies, such as social media and crisis communications, boosting agency reputation, and cultivating community partnerships. Examine and evaluate your current social media efforts. In an era where openness and authenticity are more crucial than ever, learn how to humanize your organization and gain public trust. In addition to the live presentations, the Social Media Strategy Summit will provide attendees with the opportunity to network with agency peers from across the country, allowing conference delegates to share their experiences and learn new social media strategies alongside their fellow public sector colleagues from across the US and around the world in a seamless virtual forum. For more information, please visit https://ibn.fm/YgsQR

Date: December 7-9 Venue: Virtual The forthcoming Accredited Investors Virtual Expo will be held in a completely digital format on December 7-9, 2021, by MoneyShow, a major producer of financial conferences for affluent investors, active traders, and financial advisors. Different economic and market conditions have been known to benefit different asset classes in the past. At the Accredited Investors Expo, investors and guests will learn innovative ways to diversify their portfolios for better yields, appreciation, and diversity. The Accredited Investors Virtual Expo gives conference registrants direct access to the financial industry’s greatest brains via live presentations, allowing them to interact with financial experts and fellow investors in real time. Investors will discover how to invest in esoteric private-market topics, how to exploit new crowdfunding rules to find tomorrow’s market unicorns, why preferred equity reigns supreme for today’s educated investors, and why a little bitcoin may go a long way. Here you will learn about: 

• How to Avoid Market Excesses in 2021 and Beyond
• Pre-IPO Private Placements: High Returns and High Risks
• How to Invest in Private-Market Niche Topics
• What US Investors Should Know About Private Placements in Other Countries
• Navigating 2021 in the Face of Washington’s and the Economy’s Disruption
• Pursuing Tomorrow’s Market Unicorns Using the New Crowdfunding Rules
• Accredited Investors Have a New Option in Rolling Venture Funds
• Not going out and buying the dips

More than 35 prominent market analysts, money managers, and investing gurus will present real-time analysis, guidance, and methods aimed to uncover and capitalize on opportunities across a variety of under-the-radar industries at this year’s event. Why Should You Visit It: MoneyShow has a long history of helping people become great investors and traders by providing timely investing and trading instruction from prominent specialists such as best-selling authors, market analysts, portfolio managers, award-winning financial journalists, and newsletter editors. MoneyShow’s interactive environment provides a unique style of live, interactive interaction for our audience of over one million passionate investors and traders, resulting in an unrivaled experience for both the expert and the investor or trader. They continue to broaden the dissemination of our expert comments through virtual events, face-to-face forums, social media, and in-depth courses that teach and advise qualified investors and traders to outperform the market, thanks to their continual network expansion. Everyone who attends each session is energized, empowered, and educated. For more information about this event, please visit https://ibn.fm/wERbk

• Since January, The Lightning Network has seen a growth rate of over 205%, according to company co-founder and CEO Shone Anstey
• Mid-November, LQwD took part in the Adopting Bitcoin – A Lightning Summit in El Salvador, a conference that brought together renowned industry experts in the Bitcoin and Lightning Network Community to discuss the future of money and payments in Central America and abroad
• LQwD announced that it spent a total of C$9.2 million (US$7.17 million) to purchase 150 Bitcoins, with an average cost of approximately C$61,000 (US$48,000) per Bitcoin. This purchase further strengthens the company’s strategic growth initiative

The Co-Founder, Chairman, and CEO of LQwD FinTech (TSX.V: LQWD) (OTCQB: LQWDF), Shone Anstey, was recently featured on the InvestorBrandNetwork’s The Bell2Bell Podcast to discuss his company’s business model and proven track record in the cryptocurrency industry (https://ibn.fm/GIwdY). LQwD is a financial technology company focused on the creation of an enterprise-grade infrastructure that drives Bitcoin adoption. As a Lightning Network service provider, LQwD recently released its proprietary Lightning Network Platform as a Service (“PaaS”) – lqwd.tech, which allows users to easily create a node and payment channel on the network. “We abstract away all of the complications. You hit a button, and you can integrate the API into your system and get going on the Lightning Network very, very seamlessly,” Anstey explained. “That platform is live and running; Our routing nodes help transactions get where they need to go, and, in exchange, we actually earn fees off of it. Last announced, we have 150 Bitcoin on the balance sheet, and we’re continuing to put that Bitcoin to use.” According to the LQwD CEO, the company has had a very busy year following its going public and raising over $13 million in capital to buy Bitcoin, hire more developers and launch its products. The company remains committed to improving access to the Lightning Network and offering users the possibility of conducting fast and seamless transactions, and is working toward this goal by developing strategic partnerships with key cryptocurrency wallets and exchanges. “We continue to add some key advisors from the space; we’ve signed deals with key wallets like Breez; we’ve signed deals with big exchanges such as Netcoins and continued to get our brand out there. We’ve made some big leaps and strides in an environment that is growing really quickly,” he explained, underlining that the Lightning Network itself has grown by more than 205% since January. “We’re right in the thick of it, and we’re the only public company in the world focused on the Bitcoin Lightning Network. We’re going to continue to put our stamp on that position. We have just an excellent team, which is a really big help in driving everything forward. We’ve had success in the past, and we know where we’re going with the technology,” Anstey added. To further popularize its PaaS offering, LQwD took part in the Adopting Bitcoin – A Lightning Summit in El Salvador mid-November. El Salvador is one of the few countries that adopted Bitcoin as legal tender, which contributed to much of the Lightning Network’s explosive growth this year. The conference brought together renowned industry experts in the Bitcoin and Lightning Network Community to discuss the future of money and payments in Central America and abroad (https://ibn.fm/stCAV). LQwD also took this opportunity to announce that it was increasing its Bitcoin holdings. As of the conference, LQwD spent a total of C$9.2 million (US$7.17 million) to purchase 150 Bitcoins, with an average cost of approximately C$61,000 (US$48,000) per Bitcoin. This purchase further strengthens the company’s strategic growth initiative to accumulate Bitcoin as a reserve asset. For more information, visit the company’s website at www.LQwDFinTech.com. NOTE TO INVESTORS: The latest news and updates relating to LQWDF are available in the company’s newsroom at https://ibn.fm/LQWDF

• Pharmaceutical company Tryp Therapeutics is advancing research into the ability to treat unmet medical needs by using synthetic psychedelic drug candidates generally regarded as illegal and of no practical value under federal drug standards
• The company is demonstrating its faith in the potential of psychedelic medicine by advancing its proprietary TRP-8802 psilocybin candidate toward Phase 2a drug trials through the FDA’s Investigational New Drug process
• The FDA has notified the company that its review of the IND for using TRP-8802 to treat fibromyalgia is complete and a trial planned in conjunction with the University of Michigan may proceed to patient enrollment
• Tryp is also preparing Phase 2a drug trials for testing TRP-8802 in treating eating disorders at the University of Florida, and for treating phantom limb pain and complex regional pain syndrome

Psychedelic drug medical research firm Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) has received final U.S. Food and Drug Administration (“FDA”) approval to get under way with its planned clinical study of its synthetic psilocybin drug candidate TRP-8802 for treating fibromyalgia. “The upcoming Phase 2a study with the University of Michigan for fibromyalgia represents a significant milestone for Tryp’s clinical programs,” Tryp Chairman and CEO Greg McKee stated in the Dec. 2 announcement (https://ibn.fm/aAqGr). “We are eager to begin enrolling patients in the study next year considering the significant, unmet needs of fibromyalgia patients.” The U-M study involves 25 mg dosing of TRP-8802 and combining that with psychotherapy under the care of trained therapists to “create the proper mindset for the neuroplasticity benefits of psilocybin to take full effect” (https://ibn.fm/yJyY8), helping the patients’ brains adapt and change beneficially so that they can overcome the deleterious effects of fibromyalgia by disrupting “neural connections that have been reported for nociplastic pain indications,” according to the announcement. The fibromyalgia study is the first of several Phase 2a trials Tryp Therapeutics anticipates for its synthetic psilocybin product. The company also plans to test TRP-8802’s efficacy in treating phantom limb pain, complex regional pain syndrome (“CRPS”) and select eating disorders. The company has already filed an Investigational New Drug (“IND”) application with the FDA for treating overeating disorders in conjunction with the University of Florida, similar to the U-M trial for fibromyalgia, but the FDA has requested some modifications to the UF project before the trial can proceed. The company is working with testing partners in the University of California’s educational system to prepare IND filings for the TRP-8802 trials treating phantom limb pain and CRPS. “Compared to other companies in the psychedelic drug development space, we’re going to have these four phase 2a clinical trials, which puts us in pretty rarefied air on top of the fact that we’re working in some therapeutic areas with patients that that really not a lot of other companies are looking at this time,” McKee said in a told Trader TV interview (https://ibn.fm/zjRTE). According to the company, its trial for examining TRP-8802’s effects on fibromyalgia patients will be one of the first of such evaluations of synthetic psilocybin in a Phase 2 study. The U-M study, under the direction of Kevin Boehnke, a research investigator in the Department of Anesthesiology and the Chronic Pain and Fatigue Research Center, will enroll 20 fibromyalgia patients for the open label clinical trial. It will establish analytical endpoints related to poor sleep quality, depression, anxiety and other conditions common to fibromyalgia patients. Following completion of the 2a trials, Tryp plans Phase 2b trials using its drug candidate TRP-8803 to more effectively alleviate pain and addiction by using a novel route of administration across the blood-brain barrier that is expected to lead to more precise control over the patient’s psychedelic experience during the treatment. For more information, visit the company’s website at www.TrypTherapeutics.com. NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF

• The cannabis industry in California and the United States is undergoing a metamorphosis, reflecting scores of new marijuana markets and business opportunities for cultivators, manufacturers and retailers within the sector
• American Cannabis Partners, a multi-state, vertically integrated operator with cultivation operations across the states of Michigan and California has sought to differentiate itself through its high-quality end product
• The company, which boasts a strong personal and positive relationship with Jamaica and its people, has aligned its production processes with traditional Jamaican cultivation techniques, resulting in greater production yields, higher THC levels and more pronounced terpenes
• ACP recently revealed that it had already pre-sold the entire 2021 crop comprised of their three, patent pending cannabis strains

In June 2021, a new marijuana store was inaugurated within San Francisco’s Union City area. While a new marijuana store opening is rarely a momentous affair in California, the store in question was located within the centrally-located Union Landing shopping center, a development which also housed a Walmart, Best Buy and other high-street retail stores, marking a dramatic shift from the recent past during which cannabis retailers would be obliged to locate in less desirable industrial areas (https://ibn.fm/WPgwN). California’s legal marijuana industry has undergone a stunning transformation ever since the consumption of recreational cannabis was decriminalized in January 2018, with the new store opening in San Francisco’s Union Landing mall a clear illustration of the sector’s broadening commercial prospects and mainstream appeal. American Cannabis Partners (“ACP”), a multi-state 100% organic cannabis cultivation company headquartered within Northern California’s Emerald Triangle, has sought to capitalize on the sector’s exponential growth rates through a diversified cultivation operation spanning the United States. American Cannabis Partners has centered its business model around three key pillars: the acquisition of prime, arable, agricultural land; the development of proprietary assets; and ongoing cultivation operations. Led by a seasoned management team with over 30 years of experience within the cannabis sector, ACP now operates over 540,000 square feet of licensed canopy space for cultivation spread across the states of California and Michigan, with the company possessing the second-largest growing license within the latter state. With an ever-increasing number of North American geographies legalizing both the medical and recreational use of marijuana, cannabis research, investment, cultivation, and product development have all been evolving at a rapid pace. While much of the ongoing research has focused on the myriad potential that cannabis holds for millions suffering from a variety of health complaints around the world, cannabis producers have also sought to cater to the evolving tastes of an increasingly discerning customer base. American Cannabis Partners has designed its business model to help ensure the quality and diversity of its organic end product, a step which should assist in boosting the company’s profile and competitiveness in the event of a fully legalized U.S. market. Moreover, the company, which has long prided itself on its close personal and positive relationship with Jamaica and its people, has sought to align traditional Jamaican cultivation techniques within its cannabis cultivation, harvesting and curing process, methods which have resulted in a superior product, faster growth rates, greater production yields, higher THC levels, and enhanced terpene bouquets (https://ibn.fm/oyJb8). The level of exacting detail and care paid to their plants, as well as their adherence to sustainable Jamaican production practices, have led the company to produce some of the most sought-after flowers in the United States, with ACP recently revealing that its new, patent pending strains marketed under their wholly owned in-house ZUK brand had already seen its entire crop presold for 2021. For more information, visit the company’s website at www.ACPFarms.com. NOTE TO INVESTORS: The latest news and updates relating to American Cannabis Partners are available in the company’s newsroom at https://ibn.fm/ACP